FDA Approves 5 New Novel Drugs in 2026

FDA Novel Drug Approvals

Published February 27th, 2026

Detected March 13th, 2026

Summary

The FDA has announced the approval of five new novel drugs in 2026 for various medical conditions. These approvals include treatments for achondroplasia, hyperarginemia, schizophrenia, bipolar disorder, atopic dermatitis, and Menkes disease. The agency updated its list of novel drug therapy approvals.

View original document View source feed page

What changed

The U.S. Food and Drug Administration (FDA) has published a notice detailing the approval of five novel drugs in 2026. These drugs, including Yuviwel, Loargys, Bysanti, Adquey, and Zycubo, target a range of conditions such as achondroplasia, hyperarginemia, schizophrenia, bipolar I disorder, atopic dermatitis, and Menkes disease. The notice provides the drug names, active ingredients, approval dates, and their initial FDA-approved uses, with a disclaimer to consult the official Prescribing Information for comprehensive details.

This document serves as an informational update for the pharmaceutical industry and healthcare professionals. While it does not impose new compliance obligations or deadlines, it highlights recent advancements in drug therapy. Drug manufacturers and pharmaceutical companies should note these approvals as they relate to the evolving landscape of available treatments and may inform future research and development strategies. The information is current as of February 27, 2026.

Source document (simplified)

What are "Novel" Drugs?

"Novel" drugs are new drugs never before approved or marketed in the U.S. See Drugs@FDA for information about all of CDER’s approved drugs and biological products.

FDA Novel Drug Therapy Approvals for 2026

| No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date* |
| --- | --- | --- | --- | --- |
| 5. | Yuviwel | navepegritide | 2/27/2026 | To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses |
| 4. | Loargys | pegzilarginase-nbln | 2/23/2026 | To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction |
| 3. | Bysanti | milsaperidone | 2/20/2026 | To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder |
| 2. | Adquey | difamilast | 2/12/2026 | To treat mild to moderate atopic dermatitis |
| 1. | Zycubo | copper histidinate | 1/12/2026 | To treat Menkes disease |
*The listed “FDA-approved use” on this page is for presentation purposes only. To see the FDA-approved conditions of use [e.g., indication(s), population(s), dosing regimen(s)] for each of these products, please see the most recently approved Prescribing Information (or Label) available at Drugs@FDA. You can search by drug name, active ingredient, or application number.